Deciphera Pharmaceuticals Inc
NASDAQ:DCPH
Deciphera Pharmaceuticals Inc
Accounts Payable
Deciphera Pharmaceuticals Inc
Accounts Payable Peer Comparison
Competitive Accounts Payable Analysis
Latest Figures & CAGR of Competitors
Company | Accounts Payable | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Deciphera Pharmaceuticals Inc
NASDAQ:DCPH
|
Accounts Payable
$19.5m
|
CAGR 3-Years
18%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Accounts Payable
$31.3B
|
CAGR 3-Years
15%
|
CAGR 5-Years
22%
|
CAGR 10-Years
18%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Accounts Payable
$622m
|
CAGR 3-Years
3%
|
CAGR 5-Years
2%
|
CAGR 10-Years
-7%
|
|
Amgen Inc
NASDAQ:AMGN
|
Accounts Payable
$1.6B
|
CAGR 3-Years
5%
|
CAGR 5-Years
8%
|
CAGR 10-Years
6%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Accounts Payable
$351.4m
|
CAGR 3-Years
40%
|
CAGR 5-Years
34%
|
CAGR 10-Years
22%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Accounts Payable
$671.3m
|
CAGR 3-Years
7%
|
CAGR 5-Years
23%
|
CAGR 10-Years
35%
|
See Also
What is Deciphera Pharmaceuticals Inc's Accounts Payable?
Accounts Payable
19.5m
USD
Based on the financial report for Mar 31, 2024, Deciphera Pharmaceuticals Inc's Accounts Payable amounts to 19.5m USD.
What is Deciphera Pharmaceuticals Inc's Accounts Payable growth rate?
Accounts Payable CAGR 5Y
12%
Over the last year, the Accounts Payable growth was -1%. The average annual Accounts Payable growth rates for Deciphera Pharmaceuticals Inc have been 18% over the past three years , 12% over the past five years .